Figure 5
Figure 5. Megakaryocytes continue cycling in the absence of Aurka. (A) Representative flow plots of BrdU incorporation in CD41+ cells revealed that deletion of Aurka significantly increased the proportion of cycling megakaryocytes. (B) Percentage of BrdU-positive CD41+ cells in the bone marrow of WT or Aurka−/− mice 3 days after pI-pC treatment. Means ± SD are shown; n = 3. (C) In contrast, cycling Gr1+/Mac1+ cells decrease following pI-pC treatment. Representative flow plots are shown. (D) Percentage of BrdU-positive Gr1+/Mac1+ cells in the bone marrow 3 days after pI-pC treatment. Means ± SD are shown; n = 3. (E) DNA content of CD41+ cells following pI-pC treatment. (Left) Bar graph depicting means ± SD; n = 3. (Right) Representative flow cytometry plots of DNA content. Numbers refer to the 2N, 4N, and ≥8N populations. ***P < .001; **P < .01; *P < .05.

Megakaryocytes continue cycling in the absence of Aurka. (A) Representative flow plots of BrdU incorporation in CD41+ cells revealed that deletion of Aurka significantly increased the proportion of cycling megakaryocytes. (B) Percentage of BrdU-positive CD41+ cells in the bone marrow of WT or Aurka−/− mice 3 days after pI-pC treatment. Means ± SD are shown; n = 3. (C) In contrast, cycling Gr1+/Mac1+ cells decrease following pI-pC treatment. Representative flow plots are shown. (D) Percentage of BrdU-positive Gr1+/Mac1+ cells in the bone marrow 3 days after pI-pC treatment. Means ± SD are shown; n = 3. (E) DNA content of CD41+ cells following pI-pC treatment. (Left) Bar graph depicting means ± SD; n = 3. (Right) Representative flow cytometry plots of DNA content. Numbers refer to the 2N, 4N, and ≥8N populations. ***P < .001; **P < .01; *P < .05.

Close Modal

or Create an Account

Close Modal
Close Modal